Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

Gilles M. Leclerc, PhD, Shuhua Zheng, BS, Guy J. Leclerc, PhD, Joanna DeSalvo, BSc, Ronan T. Swords, MDPhDFRCPI FRCPath, Julio C. Barredo, MD

Blood (2015) 126 (23): 1327.

https://doi.org/10.1182/blood.V126.23.1327.1327

Published: 2015

Journal Articles

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Courtney DiNardo, MD, Stéphane de Botton, Daniel A Pollyea, Eytan M Stein, Amir T. Fathi, MD, Gail J Roboz, MD, Robert Collins, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Ian W. Flinn, MD PhD, Jessica K Altman, Martin S Tallman, MD, Hagop M. Kantarjian, MD, Adnan Derti, Meredith Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone, MD

Blood (2015) 126 (23): 1306.

https://doi.org/10.1182/blood.V126.23.1306.1306

Published: 2015

Journal Articles

A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy

Diana Azzam, PhD, Claude-Henry Volmar, PhD, Al-Ali Hassan, PhD, Aymee Perez, PhD, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Francisco Vega, MD PhD, Arthur Zelent, PhD, Christopher R. Cogle, MD, Claes Wahlestedt, PhD, Ronan T. Swords, MDPhDFRCPI FRCPath

Blood (2015) 126 (23): 1352.

https://doi.org/10.1182/blood.V126.23.1352.1352

Published: 2015

Journal Articles

Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia

Ronan T. Swords, MDPhDFRCPI FRCPath, Tino Schenk, PhD, Sven Stengel, PhD, Veronica Sylvina Gil, PhD, Kevin R. Petrie, PhD, Aymee Perez, PhD, Rodriguez Ana, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Arthur Zelent, PhD

Blood (2015) 126 (23): 1363.

https://doi.org/10.1182/blood.V126.23.1363.1363

Published: 2015

Journal Articles

The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro

Ronan T. Swords, MDPhDFRCPI FRCPath, Shaun Brothers, PhD, Nagi Ayad, PhD, Aymee Perez, PhD, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Ana Rodriguez, Shawn Johnstone, PhD, Jeffrey Albert, Joseph Collard, Arthur Zelent, PhD, Claes Wahlestedt, PhD

Blood (2015) 126 (23): 2552.

https://doi.org/10.1182/blood.V126.23.2552.2552

Published: 2015

Journal Articles

The Small Molecule Img-98, a Potent and Selective Inhibitor of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation Effects of ATRA in a Pre-Clinical Model of AML

Ronan T. Swords, MDPhDFRCPI FRCPath, Aymee Perez, PhD, Ana Rodriguez, Justin M. Watts, MD, Fernando Vargas, MD, Roy Elias, Hugh Y. Rienhoff, Jr., MD, Arthur Zelent, PhD

Blood (2015) 126 (23): 460.

https://doi.org/10.1182/blood.V126.23.460.460

Published: 2015

Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Blood (2015) 126 (23): 323.

https://doi.org/10.1182/blood.V126.23.323.323

Published: 2015

Journal Articles

In Acute Myeloid Leukemia (AML), Targeting the Histone Methyltransferase EZH2 Promotes Differentiation, Impairs Clonogenic Survival and Augments the Anti-Leukemic Effects of the Retinoid, All-Trans-Retinoic Acid (ATRA)

Ronan T. Swords, MDPhDFRCPI FRCPath, Aymee Perez, PhD, Ana Rodriguez, Justin M. Watts, MD, Tino Schenk, PhD, Fernando Vargas, MD, Roy Elias, Arthur Zelent, PhD

Blood (2015) 126 (23): 3786.

https://doi.org/10.1182/blood.V126.23.3786.3786

Published: 2015

NARROW

The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy

Inhibition of the PI3K/AKT/mTOR Pathway Leads to Down-Regulation of c-Myc and Overcomes Resistance to ATRA in Acute Myeloid Leukemia

The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro

The Small Molecule Img-98, a Potent and Selective Inhibitor of the Lysine Demethylase Lsd-1, Effectively Augments the Pro-Differentiation Effects of ATRA in a Pre-Clinical Model of AML

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

In Acute Myeloid Leukemia (AML), Targeting the Histone Methyltransferase EZH2 Promotes Differentiation, Impairs Clonogenic Survival and Augments the Anti-Leukemic Effects of the Retinoid, All-Trans-Retinoic Acid (ATRA)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only